Polatuzumab Vedotin: Late Stage Clinical Development to Approval

Time: 10:00 am
day: day 2- am

Details:

  • Providing an overview of the late stage clinical development of polatuzumab vedotin
  • Discussing rational combination strategy in R/R DLBCL leading to approval of polatuzumab vedotin + BR
  • Sharing the rational combination strategy in 1L DLBCL leading to positive results of the Phase III POLARIX with polatuzumab vedotin + R-CHP

Speakers: